CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 35 enrolled
Drug / intervention
Itraconazoledrug
Likely dose
Itraconazole 5mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00528190
NCT00528190Phase 4Completed
CompareCT.gov

Treatment of Aspergillus Fumigatus in Patients With Cystic Fibrosis: A Randomized, Double-blind, Placebo-Controlled Trial

Ottawa Hospital Research Institute·interventional·Posted Sep 12, 2007·Updated May 10, 2017

In Brief

A Phase 4 clinical trial evaluating Itraconazole for Cystic Fibrosis. Completed, enrolled 35 participants across 2 sites.

Detailed Summary

This clinical trial will attempt to determine whether we can improve clinical outcomes for patients with cystic fibrosis who are infected with a fungus called Aspergillus fumigatus.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCystic Fibrosis
CountriesCanada
CollaboratorsThe Hospital for Sick Children, Canadian Cystic Fibrosis Foundation, The Physicians' Services Incorporated Foundation

Timeline

Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 12, 2007
Enrollment StartOct 1, 2007
Primary CompletionAug 1, 2010
Study CompletionMay 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 18.8 years ago

Interventions

Itraconazoledrug

Oral Itraconazole 5mg/kg/day or identical placebo for 24 weeks